Printer Friendly

Sankyo Pharma GmbH to Transfer 11 Items to STADA Arzneimittel.

Tokyo, Japan, Dec 15, 2005 - (JCN) - DAIICHI SANKYO announced on December 14 that Sankyo Pharma GmbH, a subsidiary of Sankyo, has agreed with German pharmaceutical STADA Arzneimittel AG on the transfer of ethical products.

Under the agreement terms, Sankyo Pharma will transfer to STADA its 11 proprietary items including endermic antiphlogistic Mobilat and circulatory enhancer and humectant Hirudoid.

Sankyo Pharma plans to concentrate resources on ethical products provided by Sankyo including antihypertensive agent OLMETEC in order to promote its business in Europe.

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:4EUGE
Date:Dec 15, 2005
Words:92
Previous Article:Takara Bio, MolMed Announce That Phase I/II Clinical Trial of HSV-TK Gene Therapy Delivers Positive Results.
Next Article:Hitachi to Make Hitachi Mobile Wholly Owned Subsidiary.
Topics:


Related Articles
NEUROBIOLOGICAL TECHNOLOGIES SIGNS VIPRINEX PACTS.
Kyowa Medex to Take over Sales of Astellas Pharma's In Vitro Diagnostic Product UROPIECE S.
Daiichi Pharmaceutical Acquires Daiichi Suntory Pharma As Wholly Owned Subsidiary.
Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.
Daiichi Sankyo Now Authorized to Market Its Products in China.
Takeda Pharmaceutical to Establish New Sales and Marketing Company in London.
Sankyo to Launch Osteoporosis Treatment Drug in Europe.
Sanko Lifetech Transfers Animal Health Products Business to Novartis Animal Health.
Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.
Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters